 "Nifty Pharma index rises 2% as Sun Pharma, Lupin receive USFDA approval")
Shares of pharmaceutical companies were in focus with the Nifty Pharma index rising over 2 per cent to 10,623.60 levels in the intra-day deals after Sun Pharmaceutical Industries (Sun Pharma) and Lupin USFDA approval for their respective medicines.
Sun Pharma rose over 3 per cent to an intra-day high of Rs 670.90 on the National Stock Exchange (NSE) after the drug maker announced USFDA approval of XELPROS to treat open-angle Glaucoma or Ocular Hypertension. This approval is from Sun Pharma’s Halol facility.
"XELPROS is the first and only form of latanoprost that is not formulated with benzalkonium chloride (BAK), a preservative commonly used in topical ocular preparations. XELPROSTM is developed using SPARC’s proprietary Swollen Micelle Microemulsion (SMM) technology." it said in a BSE filing earlier today.
On the other hand, Lupin, too, rose 2 per cent to Rs 978.75 on the NSE after the company on Wednesday said it has received nod from the US health regulator to market its Atovaquone oral suspension used for prevention and treatment of a type of pneumonia.
The company has received approval to market generic Atovaquone oral suspension USP in the strength of 750 mg/5 mL from the United States Food and Drug Administration (USFDA), Lupin said in a BSE filing.
At 10:05 am, all the stocks in the Nifty Pharma index were trading higher in the range of 1 per cent to 4 per cent.
| COMPANY | LATEST | PREV CLOSE | GAIN( | GAIN(%) | VOLUME |
| AUROBINDO PHARMA | 799.30 | 773.85 | 25.45 | 3.29 | 1568647 |
| PIRAMAL ENTERP. | 3013.00 | 2926.50 | 86.50 | 2.96 | 173131 |
| BIOCON | 656.70 | 639.85 | 16.85 | 2.63 | 869243 |
| GLENMARK PHARMA. | 686.75 | 673.40 | 13.35 | 1.98 | 228518 |
| CADILA HEALTH. | 416.25 | 408.70 | 7.55 | 1.85 | 715915 |
| SUN PHARMA.INDS. | 661.70 | 649.90 | 11.80 | 1.82 | 2695351 |
| CIPLA | 666.75 | 656.45 | 10.30 | 1.57 | 440936 |
| DR REDDY'S LABS | 2565.95 | 2529.15 | 36.80 | 1.46 | 183259 |
| DIVI'S LAB. | 1290.10 | 1271.55 | 18.55 | 1.46 | 129873 |
| LUPIN | 969.45 | 959.35 | 10.10 | 1.05 | 1121866 |
One subscription. Two world-class reads.
Already subscribed? Log in
Subscribe to read the full story →*Subscribe to Business Standard digital and get complimentary access to The New York Times
Smart Quarterly
₹900
3 Months
₹300/Month
SAVE 25%
Smart Essential
₹2,700
1 Year
₹225/Month
SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months
Super Saver
₹3,900
2 Years
₹162/Month
Subscribe
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
SAVE 25%